BioMarin Pharmaceuticals BMRN Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's tax on share settlement?
- BioMarin Pharmaceuticals (BMRN) reported tax on share settlement of $28.18M in Q1 2026.
- How has BioMarin Pharmaceuticals's tax on share settlement changed year-over-year?
- BioMarin Pharmaceuticals's tax on share settlement decreased by 27.3% year-over-year, from $38.78M to $28.18M.
- What is the long-term trend for BioMarin Pharmaceuticals's tax on share settlement?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's tax on share settlement has grown at a 5.1% compound annual growth rate (CAGR), from $45.81M to $55.97M.
- What does tax on share settlement mean?
- Cash paid for taxes on employee stock awards.
- How do you interpret tax on share settlement?
- Higher payments correlate with higher levels of equity-based compensation vesting and employee participation in stock plans.
- How does tax on share settlement compare across companies?
- Standard for companies with significant equity-based compensation programs; peers will show similar patterns based on vesting schedules.